Opus Genetics: Asymmetric Upside With LCA5 And BEST1
Landcadia IVLandcadia IV(US:LCA) Seeking Alpha·2026-02-23 02:35

Company Overview - Opus Genetics, Inc. is a gene-therapy developer focused on inherited retinal diseases (IRDs) [1] - The company utilizes adeno-associated virus (AAV) technology aiming for a one-dose treatment for gene augmentation to repair retinal structure [1] Lead Program - The lead program of Opus Genetics is OPGx-LCA5, which targets Leber congenital amaurosis, a type of inherited retinal disease [1]

Landcadia IV-Opus Genetics: Asymmetric Upside With LCA5 And BEST1 - Reportify